Polymer Therapeutics: Polymers as Drugs, Drug and Protein Conjugates and Gene Delivery Systems: Past, Present and Future Opportunities

  • Ruth Duncan
  • Helmut Ringsdorf
  • Ronit Satchi-Fainaro
Part of the Advances in Polymer Science book series (POLYMER, volume 192)


As the 21st century begins we are witnessing a paradigm shift in medical practice. Whereas the use of polymers in biomedical materials applications -- for example, as prostheses, medical devices, contact lenses, dental materials and pharmaceutical excipients -- is long established, polymer-based medicines have only recently entered routine clinical practice [1, 2, 3, 4]. Importantly, many of the innovative polymer-based therapeutics once dismissed as interesting but impractical scientific curiosities have now shown that they can satisfy the stringent requirements of industrial development and regulatory authority approval. The latter demand on one hand a cost-effective and profitable medicine or diagnostic, and on the other hand, a safe and efficacious profile that justifies administration to patients.

The first clinical proof of concept with polymer therapeutics has coincided with the explosion of interest in the fashionable area called “nanotechnology”. This has resulted in exponential growth in the field, and an increasing number of polymer chemists are turning their attention to the “bio-nano” arena. An attempt to define “nanotechnology” is beyond the scope of this review, but suffice it to say there is widespread agreement that application of nanotechnology to medicine, either via miniaturisation or synthetic polymer and supramolecular chemistry to construct nano-sized assemblies [5, 6], offers a unique opportunity to design improved diagnostics, preventative medicines, and more efficacious treatments of life-threatening and debilitating diseases. It is thus timely for this volume of Advances in Polymer Science to review the field that has been named “polymer therapeutics” (Fig. 1).

The term “polymer therapeutics” [1] has been adopted to encompass several families of constructs all using water-soluble polymers as components for design; polymeric drugs [3, 7], polymer-drug conjugates [1, 8], polymer-protein conjugates [2, 9], polymeric micelles to which a drug is covalently bound [10], and those multi-component polyplexes being developed as non-viral vectors [11]. From an industrial standpoint, these nanosized medicines are more like new chemical entities than conventional “drug-delivery systems or formulations” which simply entrap, solubilise or control drug release without resorting to chemical conjugation. In this issue of Advances in Polymer Science, the current status of those technologies in preclinical and clinical development is reviewed, together with presentation of an emerging area of novel synthetic chemistry -- the new field of polymer genomics -- and also a description of some of the sophisticated analytical methods being developed to characterise complex polymer constructs.


Protein Conjugate Polymeric Drug Block Copolymer Micelle Deoxyribose Nucleic Acid HPMA Copolymer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Duncan R (2003) The dawning era of polymer therapeutics. Nat Rev Drug Discov 2:347–360 CrossRefGoogle Scholar
  2. 2.
    Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214–221 CrossRefGoogle Scholar
  3. 3.
    Dhal PK, Holmes-Farley SR, Mandeville WH, Neenan TX (2002) Polymeric drugs. In: Encyclopedia of Polymer Science and Technology, 3rd edn. Wiley, New York, pp 555–580 Google Scholar
  4. 4.
    Duncan R (2003) Polymer-drug conjugates. In: Budman D, Calvert H, Rowinsky E (eds) Handbook of Anticancer Drug Development. Lippincott, Williams & Wilkins, Philadelphia, pp 239–260 Google Scholar
  5. 5.
    Editorial. Nanomedicine: grounds for optimism. Lancet, pp 362, 673; (2004) NIH Roadmap for Nanomedicines, Willis RC (2004) Good things in small packages. Nanotech advances are producing mega-results in drug delivery. Modern Drug Discov p 30–36. European Science Foundation Policy Briefing (2005) ESF Scientific Forward Look on Nanomedicine 23 February 2005 ( )
  6. 6.
    Ferrari M (2005) Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5:161–171 CrossRefGoogle Scholar
  7. 7.
    Gebelein CG, Carraher CE (1985) Bioactive polymeric systems. Plenum, New York Google Scholar
  8. 8.
    Ringsdorf H (1975) Structure and properties of pharmacologically active polymers. Polym J Sci Polymer Symp 51:135–153 Google Scholar
  9. 9.
    Davis FF (2002) The origin of pegnology. Adv Drug Del Rev 54:457–458 CrossRefGoogle Scholar
  10. 10.
    Kakizawa Y, Kataoka K (2002) Block copolymer micelles for delivery of gene and related compounds. Adv Drug Deliv Rev 54:203 CrossRefGoogle Scholar
  11. 11.
    Wagner E (2004) Strategies to improve DNA polyplexes for in vivo gene transfer: will “artificial viruses” be the answer? Pharm Res 21:8–14 CrossRefGoogle Scholar
  12. 12.
    Ringsdorf H (2004) Hermann Staudinger and the future of polymer research: jubilees – beloved occasions for cultural piety. Angew Chem Int Ed 43:1064–1076 CrossRefGoogle Scholar
  13. 13.
    Morawetz H (1985) Polymers: the origins and the growth of a science. Wiley, New York Google Scholar
  14. 14.
    Lehn JM (1995) Supramolecular chemistry: concepts and perspectives. Wiley, New York Google Scholar
  15. 15.
    Watson JD, Crick FH (1953) Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature 171:737–8 CrossRefGoogle Scholar
  16. 16.
    Jatzkewitz H (1955) Peptamin (glycyl-L-leucyl-mescaline) bound to blood plasma expander (polyvinylpyrrolidone) as a new depot form of a biologically active primary amine (mescaline). Naturforsch Z 10b:27–31 Google Scholar
  17. 17.
    Breslow DS (1976) Biologically active synthetic polymers. Pure Appl Chem 46:103–13 Seymour LW (1991) Synthetic polymers with intrinsic anticancer activity. J Bioact Comp Polymers 6:178–216 Google Scholar
  18. 18.
    Regelson W (1986) Advances in intraperitoneal (intracavitary) administration of synthetic polymers for immunotherapy and chemotherapy. J Bioact Compat Polymers 1:84–106 CrossRefGoogle Scholar
  19. 19.
    Gros L, Ringsdorf H, Schupp H (1981) Polymeric antitumour agents on a molecular and cellular level. Angew Chem Int Ed 20:301–323 CrossRefGoogle Scholar
  20. 20.
    de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, van-Hoof F (1974) Lysosomotropic agents. Biochem Pharmacol 23:2495–2531 CrossRefGoogle Scholar
  21. 21.
    Duncan R (2003) Polymer-drug conjugates. In: Budman D, Calvert H, Rowinsky E (eds) Book of anticancer drug development. Lippincott, Williams & Wilkins, Philadelphia, pp 239–260 Google Scholar
  22. 22.
    Duncan R (2005) N-(2-Hydroxypropyl)methacrylamide copolymer conjugates. In: Kwon GS (ed) Polymeric drug delivery systems. Dekker, New York, pp 1–92 CrossRefGoogle Scholar
  23. 23.
    Satchi-Fainaro R, Puder M, Davies JW, Tran HT, Sampson DA, Greene AK, Corfas G, Folkman J (2004) Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nature Med 10:255–261 CrossRefGoogle Scholar
  24. 24.
    Pack DW, Hoffman AS, Pun S, Stayton PS (2005) Design and development of polymers for gene delivery. Nature Rev Drug Discov 4:581–593 Google Scholar
  25. 25.
    Duncan R, Kopecek J (1984) Soluble synthetic polymers as potential drug carriers. Adv Polymer Sci 57:51–101 Google Scholar
  26. 26.
    Bader H, Dorn K, Hupfer B, Ringsdorf H (1985) Polymeric monolayers and liposomes as models for biomembranes. How to bridge the gap between polymer science and membrane biology? Adv Polymer Sci 64:1–62 Google Scholar
  27. 27.
    Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nature Rev Drug Discov 4:145–160 CrossRefGoogle Scholar
  28. 28.
    Duncan R, Izzo L (2005) Dendrimer biocompatibility and toxicity. In: Florence AT (ed) Advanced drug delivery reviews special issue on dendrimers. in press Google Scholar

Authors and Affiliations

  • Ruth Duncan
    • 1
  • Helmut Ringsdorf
    • 2
  • Ronit Satchi-Fainaro
    • 3
  1. 1.Centre for Polymer TherapeuticsWelsh School of Pharmacy, Cardiff University, Redwood BuildingCardiffUK
  2. 2.University of MainzInstitute of Organic ChemistryMainzGermany
  3. 3.Children's Hospital Boston and Harvard Medical SchoolVascular Biology Program, Department of Surgery, 1 Blackfan CircleBoston, Massachusetts 02115USA

Personalised recommendations